Spots Global Cancer Trial Database for ixazomib
Every month we try and update this database with for ixazomib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma | NCT03492138 | Multiple Myelom... | ONC201 Ixazomib Dexamethasone | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma | NCT03492138 | Multiple Myelom... | ONC201 Ixazomib Dexamethasone | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib | NCT04079738 | AML AML, Adult | TAK-659 Ixazomib | 18 Years - | Big Ten Cancer Research Consortium | |
| Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | NCT04047797 | Recurrent Mantl... Refractory Mant... | Ixazomib Ixazomib Citrat... Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse." | NCT04998786 | Multiple Myelom... | Ixazomib Iberdomide Dexamethasone O... | 70 Years - | Nantes University Hospital | |
| A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | NCT01217957 | Multiple Myelom... | Ixazomib Lenalidomide Dexamethasone | 18 Years - | Takeda | |
| Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma | NCT02504359 | Plasma Cell Leu... Recurrent Plasm... | Allogeneic Hema... Carmustine Cytarabine Etoposide Ixazomib Citrat... Melphalan Methotrexate Peripheral Bloo... Quality-of-Life... Tacrolimus | 18 Years - 65 Years | OHSU Knight Cancer Institute | |
| Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia | NCT02400437 | Waldenstrom's M... | Ixazomib Dexamethasone Rituximab | 18 Years - | Dana-Farber Cancer Institute | |
| Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease. | NCT03225417 | Hematopoietic S... Multiple Myelom... | Ixazomib Tacrolimus Sirolimus Any prophylaxis... | 18 Years - | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | |
| A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM) | NCT03173092 | Multiple Myelom... | Ixazomib Lenalidomide Dexamethasone | 18 Years - | Takeda | |
| Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement | NCT02765854 | Recurrent Plasm... Refractory Plas... | Dexamethasone Ixazomib Lenalidomide | 18 Years - | Emory University | |
| Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone | NCT02516423 | Solitary Osseou... | ixazomib lenalidomide dexamethasone zoledronic acid | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT03763162 | Recurrent Plasm... Refractory Plas... | Bortezomib Daratumumab Dexamethasone Ixazomib Quality-of-Life... | 18 Years - | M.D. Anderson Cancer Center | |
| Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction | NCT01912222 | Advanced Solid ... Hematologic Mal... | IXAZOMIB | 18 Years - | Millennium Pharmaceuticals, Inc. | |
| A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse." | NCT04998786 | Multiple Myelom... | Ixazomib Iberdomide Dexamethasone O... | 70 Years - | Nantes University Hospital | |
| Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer | NCT03587662 | Metastatic Kidn... Metastatic Rena... SMARCB1 Negativ... Stage III Renal... Stage IV Renal ... | Doxorubicin Doxorubicin Hyd... Gemcitabine Gemcitabine Hyd... Ixazomib Ixazomib Citrat... | 12 Years - | M.D. Anderson Cancer Center | |
| UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment | NCT02499081 | Multiple Myelom... | Ixazomib | 18 Years - 75 Years | University of Arkansas | |
| Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM | NCT04009109 | Myeloma, Multip... | Lenalidomide Ixazomib Daratumumab Inj... Dexamethasone | 18 Years - 75 Years | Alliance Foundation Trials, LLC. | |
| A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma | NCT01564537 | Relapsed Multip... Refractory Mult... | Ixazomib Lenalidomide Dexamethasone Placebo | 18 Years - | Takeda | |
| A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies | NCT00830869 | Advanced Non-he... | IXAZOMIB | 18 Years - | Takeda | |
| Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL) | NCT03616782 | Mantle Cell Lym... | Ixazomib | 19 Years - | Kosin University Gospel Hospital | |
| Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib | NCT04079738 | AML AML, Adult | TAK-659 Ixazomib | 18 Years - | Big Ten Cancer Research Consortium | |
| A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT) | NCT02312258 | Multiple Myelom... | Placebo Ixazomib | 18 Years - | Takeda | |
| Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma | NCT02410694 | Multiple Myelom... | Ixazomib Thalidomide Dexamethasone | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| Bone Healing During Ninlaro Exposure | NCT04028115 | Multiple Myelom... | Ixazomib | 18 Years - | Odense University Hospital | |
| Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) | NCT03651128 | Multiple Myelom... | bb2121 Daratumumab Pomalidomide Dexamethasone Bortezomib Ixazomib Lenalidomide Carfilzomib Elotuzumab | 18 Years - | Celgene | |
| Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIB | NCT01953783 | Advanced Solid ... Lymphoma | IXAZOMIB | 18 Years - | Takeda | |
| Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis | NCT03236792 | AL Amyloidosis | Ixazomib Cyclophosphamid... Dexamethasone | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma | NCT03880123 | Liposarcoma Malignant Perip... Alveolar Soft P... Ewing Sarcoma Sarcoma | Selinexor Ixazomib | 14 Years - | Columbia University | |
| PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma | NCT03817320 | ALL, Childhood Lymphoblastic L... Lymphoblastic L... | Ixazomib Vincristine Dexamethasone Asparaginase Doxorubicin Methotrexate (I... Triple IT (Meth... Leucovorin | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma | NCT03880123 | Liposarcoma Malignant Perip... Alveolar Soft P... Ewing Sarcoma Sarcoma | Selinexor Ixazomib | 14 Years - | Columbia University | |
| Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma | NCT06050512 | Relapsed and Re... | Mezigdomide Ixazomib Dexamethasone | 18 Years - | University of Pittsburgh | |
| Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma | NCT02004275 | Multiple Myelom... | pomalidomide ixazomib dexamethasone | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease. | NCT03225417 | Hematopoietic S... Multiple Myelom... | Ixazomib Tacrolimus Sirolimus Any prophylaxis... | 18 Years - | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | |
| UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment | NCT02499081 | Multiple Myelom... | Ixazomib | 18 Years - 75 Years | University of Arkansas | |
| A Study of IXAZOMIB in Adult Patients With Lymphoma | NCT00893464 | Lymphoma | IXAZOMIB | 18 Years - | Millennium Pharmaceuticals, Inc. | |
| Bone Healing During Ninlaro Exposure | NCT04028115 | Multiple Myelom... | Ixazomib | 18 Years - | Odense University Hospital | |
| Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients | NCT03733691 | Newly Diagnosed... | Ixazomib Lenalidomide | 18 Years - 100 Years | Oncotherapeutics | |
| Ixazomib Rollover Study | NCT02924272 | Multiple Myelom... Lymphoma Amyloidosis | Ixazomib | 18 Years - | Takeda | |
| Study of Ixazomib and Erlotinib in Solid Tumors | NCT02942095 | Solid Tumors | Ixazomib Erlotinib | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma | NCT01335685 | Multiple Myelom... | Ixazomib Melphalan Prednisone | 18 Years - | Takeda | |
| Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib | NCT04079738 | AML AML, Adult | TAK-659 Ixazomib | 18 Years - | Big Ten Cancer Research Consortium | |
| Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma | NCT03492138 | Multiple Myelom... | ONC201 Ixazomib Dexamethasone | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma | NCT05183139 | Multiple Myelom... | Ixazomib Pomalidomide Lenalidomide Dexamethasone | 18 Years - | Takeda | |
| Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma | NCT02630030 | Glioblastoma | Ixazomib | 18 Years - | Emory University | |
| Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL) | NCT03547700 | Lymphoma, T-Cel... | Romidepsin Ixazomib | 18 Years - | Big Ten Cancer Research Consortium | |
| Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular Lymphoma | NCT01939899 | Follicular Lymp... | IXAZOMIB | 18 Years - | Takeda | |
| Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM | NCT04052880 | Newly Diagnosed... | Daratumumab Bortezomib Lenalidomide Dexamethasone Ixazomib | 70 Years - | Icahn School of Medicine at Mount Sinai | |
| Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients | NCT04217967 | Multiple Myelom... | Ixazomib Lenalidomide | 18 Years - | Peking Union Medical College Hospital | |
| A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma | NCT01564537 | Relapsed Multip... Refractory Mult... | Ixazomib Lenalidomide Dexamethasone Placebo | 18 Years - | Takeda | |
| Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM | NCT04052880 | Newly Diagnosed... | Daratumumab Bortezomib Lenalidomide Dexamethasone Ixazomib | 70 Years - | Icahn School of Medicine at Mount Sinai | |
| A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation | NCT03608501 | Multiple Myelom... | Ixazomib Thalidomide Dexamethasone | 18 Years - | Takeda | |
| Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular Lymphoma | NCT01939899 | Follicular Lymp... | IXAZOMIB | 18 Years - | Takeda | |
| UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination | NCT02578121 | Multiple Myelom... | Ixazomib Pomalidomide Dexamethasone | 18 Years - | University of Arkansas | |
| Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia | NCT02070458 | Recurrent Adult... Refractory Acut... | ixazomib mitoxantrone hy... etoposide cytarabine | 18 Years - 70 Years | Case Comprehensive Cancer Center | |
| Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma | NCT02898259 | B Cell Lymphoma Lymphoma | Ixazomib Lenalidomide Rituximab | 18 Years - | Case Comprehensive Cancer Center | |
| Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma | NCT01383928 | Multiple Myelom... | Ixazomib Lenalidomide Dexamethasone | 18 Years - | Takeda | |
| A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma | NCT03323151 | Mantle-Cell Lym... | Ixazomib Ixazomib Ibrutinib Ibrutinib | 18 Years - | PrECOG, LLC. | |
| Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis | NCT03236792 | AL Amyloidosis | Ixazomib Cyclophosphamid... Dexamethasone | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients | NCT04217967 | Multiple Myelom... | Ixazomib Lenalidomide | 18 Years - | Peking Union Medical College Hospital | |
| Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma | NCT03669445 | Multiple Myelom... | Ixazomib Lenalidomide Dexamethasone Daratumumab | 18 Years - 65 Years | University Hospital, Toulouse | |
| A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT) | NCT02312258 | Multiple Myelom... | Placebo Ixazomib | 18 Years - | Takeda | |
| Ixazomib Maintenance Study in Patients With AL Amyloidosis | NCT03618537 | AL Amyloidosis | Ixazomib Dexamethasone | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma | NCT01645930 | Multiple Myelom... | Ixazomib Lenalidomide Dexamethasone | 18 Years - | Takeda | |
| Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction | NCT01912222 | Advanced Solid ... Hematologic Mal... | IXAZOMIB | 18 Years - | Millennium Pharmaceuticals, Inc. | |
| Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma | NCT02168101 | Multiple Myelom... | MLN9708 | 18 Years - 70 Years | SCRI Development Innovations, LLC | |
| Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma | NCT02004275 | Multiple Myelom... | pomalidomide ixazomib dexamethasone | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Ixazomib Rollover Study | NCT02924272 | Multiple Myelom... Lymphoma Amyloidosis | Ixazomib | 18 Years - | Takeda | |
| A Study of IXAZOMIB in Adult Patients With Lymphoma | NCT00893464 | Lymphoma | IXAZOMIB | 18 Years - | Millennium Pharmaceuticals, Inc. | |
| A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | NCT01217957 | Multiple Myelom... | Ixazomib Lenalidomide Dexamethasone | 18 Years - | Takeda | |
| Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma | NCT01645930 | Multiple Myelom... | Ixazomib Lenalidomide Dexamethasone | 18 Years - | Takeda | |
| Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma | NCT02168101 | Multiple Myelom... | MLN9708 | 18 Years - 70 Years | SCRI Development Innovations, LLC | |
| Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma | NCT05722405 | Multiple Myelom... | Ixazomib plus l... Ixazomib | 18 Years - 80 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma | NCT02046070 | Multiple Myelom... | Cyclophosphamid... Ixazomib Dexamethasone | 18 Years - | Takeda | |
| Study of Ixazomib and Erlotinib in Solid Tumors | NCT02942095 | Solid Tumors | Ixazomib Erlotinib | 18 Years - | M.D. Anderson Cancer Center | |
| Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy) | NCT03888534 | Precursor Cell ... | Ixazomib | - 17 Years | Takeda | |
| Trial of Ixazomib for Kaposi Sarcoma | NCT04305691 | Kaposi Sarcoma Skin | Ixazomib Citrat... Quality-of-Life... Questionnaire A... | 18 Years - | AIDS Malignancy Consortium | |
| A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM) | NCT03173092 | Multiple Myelom... | Ixazomib Lenalidomide Dexamethasone | 18 Years - | Takeda | |
| Ixazomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma | NCT02412228 | Multiple Myelom... | Ixazomib Cyclophosphamid... Dexamethasone | 18 Years - | Brown University | |
| Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma | NCT02916771 | Smoldering Mult... | Ixazomib Lenalidomide Dexamethasone | 18 Years - | Dana-Farber Cancer Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
